BiotechTube

LNP023

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Trial Timeline

Apr 5, 2019 → Feb 9, 2022

NCT ID
NCT03896152

About LNP023

LNP023 is a phase 2 stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria. The current trial status is completed. This product is registered under clinical trial identifier NCT03896152. Target conditions include Paroxysmal Nocturnal Hemoglobinuria.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (7)

NCT IDPhaseStatus
NCT06934967Phase 3Recruiting
NCT06931691Pre-clinicalRecruiting
NCT04557462Phase 3Recruiting
NCT03955445Phase 3Recruiting
NCT03896152Phase 2Completed
NCT03832114Phase 2Completed
NCT03373461Phase 2Completed

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
41
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
DanicopanAstraZenecaPhase 3
77
LNP023NovartisPre-clinical
23
Iptacopan (LNP023)NovartisPhase 3
77
iptacopanNovartisPhase 2
52
IptacopanNovartisPre-clinical
23
IptacopanNovartisPhase 3
77
LNP023 + Eculizumab + RavulizumabNovartisPhase 3
77
LNP023NovartisPhase 3
77
LFG316 + LNP023NovartisPhase 2
52
IptacopanNovartisPhase 3
77
CrovalimabRochePhase 3
77
ABP 959 + EculizumabAmgenPhase 3
76
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
22
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
51
Humanized anti-Factor Bb monoclonal antibody + PlaceboSanofiPhase 1
32

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85